This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub
D

ASCO® 2024 Insights: "Impact of Exposure on Outcomes With Enfortumab Vedotin in Patients With Locally Advanced or Metastatic Urothelial Cancer"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Daniel Petrylak
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Daniel Petrylak
155 views
June 6, 2024

Chapters

Introduction & Enfortumab Vedotin Overview

00:00

Study Schema & Dose Modifications

01:26

Efficacy Across Different Doses & Trials

04:14

Dose Reduction Impact on Treatment Outcomes

07:30

Safety, Efficacy & Conclusion

09:45

0 Comments
Login to view comments. Click here to Login

2024 ASCO® Annual Meeting Insights Hub: GU Videos

21:54
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Prostate Cancer Take-Home Messages

Feat. E. Efstathiou
10:19
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Current Updates in RCC - Clinical Implicat…

Feat. K. Mittal
15:28
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Bladder and RCC Highlights"

Feat. K. Tawagi, N. Reizine
View All

Related Content

AUTOPLAY
Advanced Prostate Cancer Consensus Conference (APCCC)

APCCC 2026

Fri, Feb 27, 2026
International Urology Cancer Summit - IUCS

Second International Urology Cancer Summit

Fri, Sep 27, 2024
14:16
Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Summary: "Important Prostate Cancer Take-Home Mes…

Feat. E. Efstathiou
16:05
Insights from 2024 ASCO® GU Annual Meeting

Recent GU Developments and Their Clinical Implications

Feat. T. Powles, B. Rini
09:55
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future H…

Feat. E. Hamilton
20:41
2024 ASCO® Annual Meeting Insights Hub

Bladder Cancer Highlights From ASCO® 2024

Feat. G. Sonpavde
17:50
AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde
29:25
Northwestern Medicine Oncology and Hematology

Hyperprogression in Cancer Treated With Immunotherapy

Feat. Y. Chae
09:14
Robert Dreicer

AUA Advanced Prostate Cancer Guidelines: 2023 Update

21:08
Integrity CE

Updates in the Treatment and Management of Bladder Cancer

Feat. M. Galsky, B. Guercio
03:05
Benjamin L. Maughan

Testosterone Suppression and Recovery in Patients With Advanced Pros…

06:27
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Evaluation of Persistence and Adherence f…

Feat. J. Hafron
22:19
Insights from 2023 ESMO Annual Meeting

Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting …

Feat. G. Sonpavde
22:27
2024 ASCO® Annual Meeting Insights Hub

Developmental Therapeutics Highlights From ASCO® 2024

Feat. G. Sonpavde
10:19
University of Colorado Cancer Center

NCCN Guidelines Updates for the Treatment of Metastatic Urothelial C…

Feat. T. Flaig
22:07
Weill Cornell Medicine Oncology & Hematology

Urothelial Carcinoma: New Developments

Feat. C. Sternberg
17:32
Kriti Mittal

Current Updates in Urothelial Cancer: Clinical Implications for Prac…

15:28
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Bladder and RCC Highlights"

Feat. K. Tawagi, N. Reizine
14:00
Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Summary: "Key Highlights in Bladder/Urothelial Ca…

Feat. G. Sonpavde
09:45
Northwestern Medicine Oncology and Hematology

Differences Between Urologists and Medical Oncologists in the Manage…

Feat. W. Catalona
09:40
UCSF School of Medicine

Trastuzumab Deruxtecan Approval for Metastatic HER2+ Bladder Cancer

Feat. V. Koshkin
06:58
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Systemic Treatments in Favorable and Very…

Feat. M. Zarba